Clinical Report: Effective Management of Hepatic Visceral Crisis in HER2-Positive Metastatic Breast Cancer

Overview

This report details a case of a 51-year-old woman with HER2-positive metastatic breast cancer who presented with hepatic visceral crisis. Following treatment with trastuzumab and pertuzumab, combined with dose-reduced paclitaxel, the patient achieved significant clinical and biochemical recovery.

Background

Hepatic visceral crisis (HVC) is a severe complication in HER2-positive metastatic breast cancer, often leading to poor outcomes due to the exclusion of such patients from clinical trials. The management of HVC remains challenging, necessitating rapid therapeutic interventions to restore organ function. Understanding effective treatment strategies in this context is crucial for improving patient outcomes.

Data Highlights

Key Findings

• The patient presented with severe hepatic dysfunction meeting criteria for HVC.
• Initial treatment included trastuzumab and pertuzumab with dose-reduced paclitaxel.
• Biochemical markers improved significantly, with normalization of liver function tests.
• Radiologic assessments indicated a sustained partial response and treatment-related changes consistent with pseudocirrhosis.
• Continuous HER2-targeted therapy was crucial for restoring organ function despite profound hepatic failure.

Clinical Implications

This case underscores the potential for meaningful recovery in patients with HVC when treated with sustained HER2-directed therapy. Clinicians should consider early intervention strategies in similar high-risk scenarios to improve patient outcomes.

Conclusion

The management of hepatic visceral crisis in HER2-positive metastatic breast cancer can lead to significant recovery with appropriate therapy. This case contributes valuable insights for clinicians facing similar challenges.

Related Resources & Content

1. The ASCO Post, 2020 -- High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
2. The ASCO Post, 2015 -- Complexities of Targeting HER2 in Estrogen Receptor–Positive Breast Cancers
3. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) - PubMed
4. The ASCO Post — Complexities of Targeting HER2 in Estrogen Receptor–Positive Breast Cancers
5. The ASCO Post — Optimizing HER2-directed Therapy in the Clinic
6. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) - PubMed
7. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study | Medicines Awareness Service